Clinical trial
A Phase 3, Randomized,Double-Blind, Comparative Study of Micafungin (FK463) Versus Placebo as Preemptive Prophylactic Antifungal Therapy in Patients in the Intensive Care Unit
NCT00048750 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized,Double-Blind, Comparative Study of Micafungin (FK463) Versus Placebo as Preemptive Prophylactic Antifungal Therapy in Patients in the Intensive Care Unit
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 31, 2003
- Completion date
- June 30, 2003
- Enrollment
- 104 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.